Waters & Kraus, LLP
Dallas, Texas OfficeView all offices
3219 McKinney Avenue
(Collin, Dallas & Denton Cos.)
Toll Free: 800.226.9880
|Profile Visibility |
|#2 in weekly profile views out of 3,037 law firms in Dallas, Texas|
|#192 in weekly profile views out of 282,726 total law firms Overall|
Office Hours:Monday: 08:00 AM-05:00 PM
Tuesday: 08:00 AM-05:00 PM
Wednesday: 08:00 AM-05:00 PM
Thursday: 08:00 AM-05:00 PM
Friday: 08:00 AM-05:00 PM
About this office:
Waters & Kraus, LLP is a mid-sized plaintiffs' firm with a successful national practice, as well as international experience. Our attorneys focus on toxic tort litigation (asbestos/mesothelioma), consumer product liability, as well as qui tam (whistleblower) and commercial litigation. With offices in Texas and California, Waters & Kraus, LLP has litigated cases in jurisdictions across the United States on behalf of individuals from all 50 states, as well as foreign governments. To learn more about the firm and our practice, please go to www.waterskraus.com.
Statement of Practice Summary:
Mesothelioma; Asbestos Cancer; Civil Law; Class Actions; Qui Tam; Pharmaceutical; Product Liability; Toxic Torts; Asbestos Litigation; Whistleblower Litigation; International Litigation; Drug and Medical Device Litigation; Dental Medicaid Fraud; Medicare Fraud and Abuse; Birth and Childhood Injury.
Documents by Lawyers at this office
Standard Chemotherapy Regimen for Pleural Mesothelioma May Add Bevacizumab
Peter A. Kraus,Troyce G. Wolf, June 24, 2015
Malignant pleural mesothelioma may soon be getting a new standard of care. Bevacizumab may be added to the current standard chemotherapy regimen of pemetrexed and cisplatin. According to Dr. Gerald Zalcman, who recently presented a paper at the 2015 American Society of Clinical Oncology (ASCO)...
Mesothelioma Patients May Benefit From Lymphoma Drug
Peter A. Kraus,Troyce G. Wolf, April 22, 2015
Mesothelioma patients whose disease is of the epithelioid subtype may benefit from treatment with a drug that is already being used in patients with large cell lymphoma and Hodgkin’s disease. Adcetris — or brentuximab vedotin — has been shown in encouraging new research to slow...
Year Established: 1995
Languages: English and Spanish.